Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia

Journal of Psychiatric Research

Volumn 42, Issue 13, 2008, Pages 1076-1085

  Ader, Marilyn ^a   Garvey, W Timothy ^b   Phillips, Lawrence S ^c   Nemeroff, Charles B ^c   Gharabawi, Georges ^d   Mahmoud, Ramy ^e   Greenspan, Andrew ^f   Berry, Sally A ^f   Musselman, Dominique L ^c   Morein, Jacqueline ^e   Zhu, Young ^e   Mao, Lian ^e   Bergman, Richard N ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c EMORY UNIVERSITY   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^f JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Diabetes; Minorities; Olanzapine; Risperidone; Schizophrenia

Indexed keywords

INSULIN; OLANZAPINE; RISPERIDONE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ETHNIC DIFFERENCE; FEMALE; GLUCOSE HOMEOSTASIS; HISPANIC; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN LEVEL; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; INTRAVENOUS GLUCOSE TOLERANCE TEST; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBESITY; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL FUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 50049096707     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2008.01.004     Document Type: Article

References (47)

1. Ader M., Kim S.P., Catalano K.J., Ionut V., Hucking K., Richey J.M., et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 54 (2005) 862-871
2. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 156 (1999) 1686-1696
3. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 (2004) 596-601
4. Basson B.R., Kinon B.J., Taylor C.C., Szymanski K.A., Gilmore J.A., and Tollefson G.D. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. Journal of Clinical Psychiatry 62 (2001) 231-238
5. Bergman R.N. Toward physiological understanding of glucose tolerance: minimal-model approach (Lilly Lecture). Diabetes 38 (1989) 1512-1527
6. Bergman R.N., and Ader M. Atypical antipsychotics and glucose homeostasis. Journal of Clinical Psychiatry 66 (2005) 504-514
7. Bergman R.N., Ader M., Huecking K., and Van Citters G. Accurate assessment of b-cell function: the hyperbolic correction. Diabetes 51 suppl 1 (2001) S212-S220
8. Bergman R.N., Zaccaro D.J., Watanabe R.M., Haffner S.M., Saad M.F., Norris J.M., et al. Minimal model-based insulin sensitivity has greater heritability and a different genetic basis than homeostasis model assessment or fasting insulin. Diabetes 52 (2003) 2168-2174
9. Boston R.C., Stefanovski D., Moate P.J., Sumner A.E., Watanabe R.M., and Bergman R.N. MINMOD millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technology and Therapeutics 5 (2003) 1003-1015
10. Buckland P.R., Hoogendoorn B., Guy C.A., Smith S.K., Coleman S.L., and O'Donovan M.C. Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain. American Journal of Psychiatry 162 (2005) 613-615
11. Cossrow N., and Falkner B. Race/ethnic issues in obesity and obesity-related comorbidities. Journal of Clinical Endocrinology and Metabolism 89 (2004) 2590-2594
12. Cowie C.C., Harris M.I., Silverman R.E., Johnson E.W., and Rust K.F. Effect of multiple risk factors on differences between blacks and whites in the prevalence of non-insulin-dependent diabetes mellitus in the United States. American Journal of Epidemiology 137 (1993) 719-732
13. Eder U., Mangweth B., Ebenbichler C., Weiss E., Hofer A., Hummer M., Kemmler G., et al. Association of olanzapine-induced weight gain with an increase in body fat. American Journal of Psychiatry 158 (2001) 1719-1722
14. Eli Lilly and Company. Zyprexa (olanzapine): package insert; 2001.
15. Fujimoto W.Y., Bergstrom R.W., Boyko E.J., Leonetti D.L., Newell-Morris L.L., and Wahl P.W. Susceptibility to development of central adiposity among populations. Obesity Research 3 suppl 2 (1995) 179S-186S
16. Gothelf D., Falk B., Singer P., Kairi M., Phillip M., Zigel L., et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. American Journal of Psychiatry 159 (2002) 1055-1057
17. Goudie A.J., Halford J.C.G., Dovey T.M., Cooper G.D., and Neill J.C. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs (letter to the editor). Neuropsychopharmacology 28 (2003) 2209
18. Graham K.A., Perkins D.O., Edwards L.J., Barrier Jr. R.C., Lieberman J.A., and Harp J.B. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. American Journal of Psychiatry 162 (2005) 118-123
19. Gupta S., Lentz B., Lockwood K., and Frank B. Atypical antipsychotics and glucose dysregulation: a series of 4 cases. Journal of Clinical Psychiatry (Primary Care Companion) 3 (2001) 61-65
20. Haddad P.M. Antipsychotics and diabetes: review of non-prospective data. British Journal of Psychiatry 184 suppl 47 (2004) s80-s86
21. Haffner S.M., D'Agostino R.D., Saad M.F., Rewers M., Mykkanen L., Selby J., et al. Increased Insulin Resistance and insulin secretion in non-diabetic African-Americans and Hispanics compared to non-Hispanic Whites: the Insulin Resistance and Atherosclerosis Study. Diabetes 45 (1996) 742-748
22. Hardy T.A., Meyers A.L., Yu J., Shankar S.S., Steinberg H.O., and Porksen N.K. Acute insulin response and β-cell compensation in normal subjects treated with olanzapine or risperidone for 2 weeks. Diabetes Care 30 (2007) 157-158
23. Henderson D.C., Cagliero E., Copeland P.M., Borba C.P., Evins E., Hayden D., et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents. Archives of General Psychiatry 62 (2005) 19-28
24. Jin H., Meyer J.M., and Jeste D.V. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Annals of Clinical Psychiatry 14 (2002) 59-64
25. Jones B., Basson B.R., Walker D.J., Crawford A.M.K., and Kinon B.J. Weight change and atypical antipsychotic treatment in patients with schizophrenia. Journal of Clinical Psychiatry 62 suppl 2 (2001) 41-44
26. Kahn B.B., and Flier J.S. Obesity and insulin resistance. Journal of Clinical Investigation 106 (2000) 473-481
27. Kroeze W.K., Hufeisen S.J., Popadak B.A., Rannock S.M., Steinberg S., Ernsberger P., et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28 (2003) 519-526
28. Lee A., Ader M., Bray G.A., and Bergman R.N. Diurnal variation in glucose tolerance: cyclic suppression of insulin action and insulin secretion in normal weight, but not obese subjects. Diabetes 41 (1992) 750-759
29. Lee E., Leung C.M., and Wong E. Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. Journal of Clinical Psychiatry 65 (2004) 864-866
30. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353 (2005) 1209-1223
31. Lillioja S., and Bogardus C. Obesity and insulin resistance: lessons learned from the Pima Indians. Diabetes Metabolism Review 5 (1988) 517-540
32. McIntyre R.S., Mancini D.A., and Basile V.S. Mechanisms of antipsychotic-induced weight gain. Journal of Clinical Psychiatry 62 suppl 23 (2001) 23-29
33. Murashita M., Kusumi I., Inoue T., Takahashi Y., Hosoda H., and Kangawa K. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 30 (2005) 106-110
34. Nakazato M., Murakami N., Date Y., Kojima K., Matsuo H., Kangawa K., et al. A role for ghrelin in the central regulation of feeding. Nature 409 (2001) 194-198
35. Ota M., Mori K., Nakashima A., Kaneko Y.S., Fujiwara K., Itoh M., et al. Peripheral injection of risperidone, an atypical antipsychotic, alters the body weight gain of rats. Clinical and Experimental Pharmacology and Physiology 29 (2002) 980-989
36. Pi-Sunyer X.F. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Institutes of Health, National Heart, Lung, and Blood Institute (1998) 1-178
37. Porte Jr. D. B-cells in type II diabetes mellitus (Banting Lecture). Diabetes 40 (1991) 166-180
38. Reynolds G.P., Zhang Z.J., and Zhang X.B. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359 (2002) 2086-2087
39. Ryan M.C.M., Flanagan S., Kinsella U., Keeling F., and Thakore J.H. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Science 74 (2004) 1999-2008
40. Simpson M.M., Goetz R.R., Devlin M.J., Goetz S.A., and Walsh B.T. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods. Journal of Clinical Psychiatry 62 (2001) 694-700
41. Sowell M., Mukhopadhyay N., Cavazzoni P., Carlson C., Mudaliar S., Chinnapongse S., et al. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. Journal of Clinical Endocrinology and Metabolism 88 (2003) 5875-5880
42. Sowell M.O., Mukhopadhyay N., Cavazzoni P., Shankar S., Steinberg H.O., Breier A., et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. Journal of Clinical Endocrinology and Metabolism 87 (2002) 2918-2923
43. Thakore J.H., Mann J.N., Vlahos I., Martin A., and Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. International Journal of Obesity 26 (2002) 137-141
44. Togo T., Hasegawa K., Miura S., Hosojima H., Kojima K., Shoji M., Kase A., et al. Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology 172 (2004) 230-232
45. Virkkunen M., Wahlbeck K., Rissanen A., Naukkarinen H., and Franssila-Kallunki A. Decrease of energy expenditure causes weight increase in olanzapine treatment: a case study. Pharmacopsychiatry 35 (2002) 124-126
46. Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology, Jul 18 2007 (Epub ahead of print).
47. Zhang Z.J., Yao Z.J., Liu Y., Fang Q., and Reynolds G.P. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. British Journal of Psychiatry 184 (2004) 58-62